All Covid-19 updates and resources can be found here: COVID-19 INFORMATION FOR CF COMMUNITY
Skip To Content
Volunteer Advocate


As part of Canada’s drug review and reimbursement process, new drugs are reviewed by Canada’s Health Technology Assessment (HTA) bodies who consider the cost effectiveness of new medicines. The main HTA bodies In Canada are:


CADTH is an independent, not-for-profit organization responsible for providing informed decisions about the cost effectiveness of drugs and medical devices in Canada. CADTH provides non-binding recommendations to federal, provincial and territorial governments on whether or not to cover the cost of medications through their public plans. 

CADTH recommendations are used by all Canadian provinces, except Quebec, which has its own review board, INESSS. Some provinces, like B.C., also have province specific reviews; unlike Quebec, these provinces also rely on the CADTH decision to inform their reimbursement decisions. That said, provinces do not have to adhere to the recommendations, which are non-binding, and can decide to cover drugs individually.

For Quebec residents, INESSS conducts its own cost-effectiveness reviews of new medicines. It issues recommendations concerning their adoption, use and coverage by the public plan, and develops guides to clinical practice in order to ensure their optimal use.

Since 2018, reviews of new drugs conducted by CADTH and INESSS can occur alongside the Health Canada review, if the manufacturer applies for and is granted an “aligned review”. In this case, a review takes approximately 6-12 months. If the drug does not receive an aligned review, CADTH and INESSS review after Health Canada has approved the medicines for sale in Canada, and a review can take up to a year or more. 

Cystic Fibrosis Canada advocates for all cystic fibrosis treatments to receive a fast and fair review within the Canadian drug review and reimbursement system. We continue to work with the CF community and our community partners to advocate for a nation-wide strategy to improve access to drugs for rare diseases and CF medicines, calling on our federal and provincial governments to work with private insurers, employers,manufacturers, clinicians, researchers, health charities and patient groups to implement this strategy now. 


On July 8, 2021, CADTH shared their draft recommendation for Trikafta. Despite a positive recommendation to list the drug, the overly restrictive criteria CADTH recommended was not what we had hoped for. Please see our press release for more details.

Patient, physician and researcher groups are provided a 10 day window to provide feedback on draft recommendations. In collaboration with CF clinicians and researchers , Cystic Fibrosis Canada made multiple submissions to provide feedback to CADTH. Read the three submissions made to CADTH to respond to their draft recommendation for Trikafta:


Thank you to nearly 1,500 people impacted by cystic fibrosis who completed Cystic Fibrosis Canada’s community survey to help inform our patient group submissions to CADTH, INESSS, and BC Pharmacare. The survey closed on January 26, 2021.

Each of the review bodies mentioned conduct a cost effectiveness review of new medications. As part of their reviews of Trikafta, these organizations want to learn more about the experience of people living with cystic fibrosis and their caregivers, which is where our submissions, with your input, play a role.